Allergan PLC. (AGN) Shares Sold by Tredje AP fonden
Tredje AP fonden reduced its holdings in Allergan PLC. (NYSE:AGN) by 6.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 63,941 shares of the company’s stock after selling 4,600 shares during the period. Tredje AP fonden’s holdings in Allergan PLC. were worth $15,543,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of AGN. Waldron LP purchased a new position in shares of Allergan PLC. in the first quarter valued at approximately $348,000. Grisanti Capital Management LLC lifted its position in shares of Allergan PLC. by 1.5% in the first quarter. Grisanti Capital Management LLC now owns 30,817 shares of the company’s stock valued at $7,363,000 after acquiring an additional 460 shares in the last quarter. Moody Lynn & Lieberson LLC lifted its position in shares of Allergan PLC. by 32.9% in the first quarter. Moody Lynn & Lieberson LLC now owns 51,487 shares of the company’s stock valued at $12,301,000 after acquiring an additional 12,744 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in shares of Allergan PLC. by 10.4% in the first quarter. Daiwa Securities Group Inc. now owns 61,211 shares of the company’s stock valued at $14,624,000 after acquiring an additional 5,763 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV lifted its position in shares of Allergan PLC. by 93.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 13,389 shares of the company’s stock valued at $3,199,000 after acquiring an additional 6,478 shares in the last quarter. 82.02% of the stock is currently owned by institutional investors.
Several equities analysts have recently weighed in on AGN shares. ValuEngine downgraded Allergan PLC. from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Cowen and Company set a $400.00 target price on Allergan PLC. and gave the company a “buy” rating in a research report on Thursday, June 8th. Mizuho decreased their target price on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating on the stock in a research report on Friday, June 9th. Royal Bank Of Canada set a $284.00 target price on Allergan PLC. and gave the company a “buy” rating in a research report on Monday, June 12th. Finally, Cantor Fitzgerald started coverage on Allergan PLC. in a research report on Friday, June 16th. They issued a “neutral” rating and a $231.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company. Allergan PLC. currently has an average rating of “Buy” and an average target price of $273.34.
WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.dailypolitical.com/2017/09/25/allergan-plc-agn-shares-sold-by-tredje-ap-fonden.html.
Shares of Allergan PLC. (AGN) opened at 204.65 on Monday. The firm’s 50-day moving average price is $229.79 and its 200 day moving average price is $236.07. The firm has a market cap of $68.42 billion, a PE ratio of 6.24 and a beta of 1.18. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80.
Allergan PLC. (NYSE:AGN) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. During the same quarter in the prior year, the company posted $3.35 EPS. The business’s revenue for the quarter was up 8.8% compared to the same quarter last year. On average, equities research analysts forecast that Allergan PLC. will post $16.26 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Friday, August 18th were paid a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.37%. The ex-dividend date of this dividend was Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is presently 9.95%.
Allergan PLC. Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.